Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christian Grommes, Anna P. Dabrowska-Iwanicka, Han W. Tun, Christopher D'Angelo, Adolfo De La Fuente, Itai Levi, Lakshmi Nayak, David Lavie, Alessia Castellino, Michal Taszner, Praveen Ramakrishnan, Laurence Schenone, Andrés José María Ferreri, Teresa Calimeri, Luca Nassi, Caroline Houillier, Anna Schmitt, Gaurav S. Choudhary, Wanying Zhao, Grzegorz S. Nowakowski
Institutions: Memorial Sloan Kettering Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Mayo Clinic in Florida, University of Nebraska Medical Center, MD Anderson Cancer Center Madrid, Soroka Medical Center, Dana-Farber Cancer Institute, Hadassah Medical Center, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Gdańsk Medical University, The University of Texas Southwestern Medical Center, Centre Hospitalier Régional et Universitaire de Nancy, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Pitié-Salpêtrière Hospital, Institut Bergonié, Curis (United States), Mayo Clinic
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410816814